Financial Performance - The group's revenue increased by 40.1% to RMB 1,526.9 million for the six months ended June 30, 2024, compared to RMB 1,090.1 million for the same period in 2023[1]. - Gross profit rose by RMB 20.7 million to RMB 173.2 million, while the gross profit margin decreased from 14.0% to 11.3% due to increased procurement costs from RMB depreciation[1]. - Net profit attributable to the company increased by RMB 4.3 million to RMB 23.9 million for the reporting period, compared to RMB 19.6 million for the same period in 2023[1]. - Basic and diluted earnings per share for the period were RMB 1.17, up from RMB 0.965 for the six months ended June 30, 2023[1]. - The company reported a pre-tax profit of RMB 67.994 million for the reporting period, compared to RMB 42.769 million for the same period in 2023[2]. - The pharmaceutical sales revenue for the reporting period reached RMB 1,515.8 million, an increase of RMB 439.7 million or 40.9% compared to the same period last year[28]. - The group’s gross profit was RMB 173.2 million, an increase of RMB 20.7 million compared to RMB 152.5 million in the same period of 2023, with a gross margin decrease from 14.0% to 11.3%[38]. - The cost of goods sold for the six months ended June 30, 2024, was RMB 1,349,568,000, compared to RMB 932,718,000 for the same period in 2023, reflecting an increase of approximately 44.5%[21]. - Income tax expense for the six months ended June 30, 2024, was RMB 44,124,000, compared to RMB 23,174,000 for the same period in 2023, indicating an increase of approximately 90.2%[22]. Revenue Segmentation - For the six months ended June 30, 2024, the total revenue from the import pharmaceutical sales segment was RMB 1,515,758 thousand, while the total revenue from the aesthetic medicine research and manufacturing segment was RMB 11,093 thousand, and the aesthetic services segment contributed RMB 1,526,851 thousand[10]. - The total revenue from customer contracts for the six months ended June 30, 2024, was RMB 1,090,126,000, compared to RMB 1,526,851,000 for the same period in 2023, representing a decrease of approximately 28.6%[16]. - Pharmaceutical sales accounted for RMB 1,076,097,000 of the total revenue for the six months ended June 30, 2024, while aesthetic medical services contributed RMB 14,029,000[16]. - The major customer contributed approximately RMB 257,142,000, representing over 10% of the total revenue for the six months ended June 30, 2024, compared to RMB 204,155,000 for the same period in 2023[18]. Assets and Liabilities - As of June 30, 2024, total assets amounted to RMB 1,819,354 thousand, with total liabilities of RMB 1,174,650 thousand, resulting in a net asset position[13]. - Total current assets decreased to RMB 1,349.093 million from RMB 1,433.283 million as of December 31, 2023[4]. - Total non-current assets increased to RMB 470.261 million from RMB 457.395 million as of December 31, 2023[4]. - The total liabilities as of December 31, 2023, were RMB 1,262,626 thousand, with total assets of RMB 1,890,678 thousand, indicating a stable financial position[14]. - The debt ratio increased to 52.6% as of June 30, 2024, from 47.2% on December 31, 2023, reflecting a rise in net liabilities to RMB 716.8 million against total equity of RMB 644.7 million[51]. Cash Flow - The net cash used in operating activities for the six months ended June 30, 2024, was RMB 268.0 million, compared to a net cash inflow of RMB 425.8 million for the same period in 2023, primarily due to increases in trade receivables and decreases in trade payables[52]. - The net cash used in investing activities was RMB 21.5 million for the reporting period, a decrease of RMB 26.1 million from RMB 47.6 million in the same period of 2023, mainly due to reduced payments for right-of-use assets[53]. - The net cash generated from financing activities was RMB 115.6 million for the reporting period, compared to a net cash outflow of RMB 188.5 million for the same period in 2023, primarily due to net bank borrowings[53]. - As of June 30, 2024, cash and cash equivalents totaled RMB 282.0 million, down from RMB 520.8 million on December 31, 2023, reflecting a net decrease of RMB 173.9 million[54]. Dividends and Shareholder Returns - The company did not declare any interim dividend for the reporting period, consistent with the previous period[1]. - The company declared a final dividend of HKD 0.39 per share for the year ended December 31, 2023, totaling RMB 7,218,000, compared to RMB 18,112,000 for the same period in 2022[23]. - The company has not declared any interim dividends for the reporting period ending June 30, 2023[70]. Operational Developments - The group has completed over 50% of the clinical trial enrollment for the "Girl's Needle" project, with completion expected in July 2024, one month ahead of schedule[30]. - The group is actively developing new medical aesthetic products, with ongoing research on new materials and medical devices aimed at wrinkle improvement[30]. - The group aims to enhance market expansion and optimize product structure to improve customer satisfaction and reduce costs and risks[29]. - The group plans to continue expanding its marketing network and enhance the management of its sales team to drive growth in the second half of 2024[32]. Employee and Human Resources - Employee costs totaled RMB 24.2 million for the reporting period, slightly down from RMB 24.4 million for the six months ended June 30, 2023[61]. - The group employed 303 employees as of June 30, 2024, maintaining stable staffing levels without significant turnover or labor disputes[61]. - The group emphasizes the importance of human resources as a key asset, providing competitive compensation and professional training programs to motivate employees[64]. Risk Management - The company identified key risks including reliance on a limited number of suppliers and potential currency fluctuations affecting costs and revenues[62]. - The management is actively involved in assessing significant business risks and implementing appropriate risk management measures[63]. Compliance and Governance - The audit committee is responsible for reviewing and monitoring the financial reporting system and internal control procedures of the group[72]. - The interim results announcement and the 2024 interim report will be published on the Hong Kong Stock Exchange and the company's website[72]. - The company has adhered to all applicable laws and regulations in the Cayman Islands, British Virgin Islands, Hong Kong, and China during the reporting period[66].

Financial Performance - The Group's revenue increased by 11.8% to RMB2,540.1 million for the Reporting Period (2022: RMB2,271.5 million), driven by a sales increase of approximately RMB249.8 million in human albumin injections[37]. - Net profit decreased by 39.0% to RMB42.4 million for the Reporting Period (2022: RMB69.5 million), primarily due to increased administration expenses related to the expansion in research and manufacturing of aesthetic medicine and medical beauty segments[36]. - Gross profit increased by RMB17.4 million to RMB323.3 million, while gross profit margin decreased from 13.5% in 2022 to 12.7% for the Reporting Period[28]. - Basic and diluted earnings per share were RMB0.02 for the Reporting Period (2022: RMB0.03)[35]. - The Group recorded revenue of RMB2,540.1 million for the Reporting Period, representing an increase of RMB268.6 million, or 11.8% compared to RMB2,271.5 million in 2022[100]. - The Group's net profit for the Reporting Period was RMB42.4 million, a decrease of RMB27.1 million compared to RMB69.5 million in 2022[109]. - Other income and gains amounted to RMB14.6 million, representing a decrease of RMB10.6 million compared to 2022, mainly due to a decrease in foreign exchange gains[104]. Use of Proceeds - Approximately 60% of the net proceeds from the 2022 Placing, amounting to approximately HK$116.9 million, will be allocated for strategic acquisitions and development of new projects/products in the medical aesthetic field[8][11]. - Approximately 40% of the net proceeds from the 2022 Placing, around HK$78.0 million, will be used for costs related to the development of polycaprolactone microsphere facial filler and its injection materials[14]. - The net proceeds from the 2022 Placing, after deducting commissions and related expenses, totaled approximately HK$194.9 million, with a net price of HK$1.22 per share[14]. - Approximately HK$133.1 million of the net proceeds from the 2022 Placing had been utilized, with unutilized net proceeds as of December 31, 2022, amounting to approximately HK$61.8 million[192]. - During the reporting period, approximately HK$31.0 million of net proceeds from the 2022 Placing had been used for various purposes[192]. Market and Product Development - The company anticipates that blood products will become one of the most prosperous sub-sectors in the pharmaceutical industry over the next 2-3 years due to increased demand and supply shortages[42]. - The company is focusing on innovation and development in the field of blood products to address changing healthcare needs due to demographic shifts[44]. - The Group's strategic layout in blood products, particularly human albumin, is expected to maintain strong market demand due to steady growth in national medical resource needs[178]. - The Group's aesthetic products research and development is progressing, with the Girl Needle project entering clinical trials scheduled for completion in the second half of 2025[80]. - The Group has completed the development and registration of the Girl Needle Type S, with clinical trials preparations currently underway[155]. - The Group's marketing strategy has shifted to a more targeted approach, focusing on specific customer areas and promotional service providers[149]. Operational Efficiency and Management - The Group maintains stable long-term relationships with suppliers and distributors by providing guidance, training, and support for marketing and promotional activities[3]. - The management is committed to effective risk management and internal control measures to enhance operational efficiency[22]. - The Group is committed to innovation and development, focusing on expanding new business areas while enhancing internal management and risk control capabilities[180]. - The Group's operational strategy includes strengthening relationships with suppliers to mitigate risks associated with supply chain dependencies[184]. - The Group has optimized its marketing network, focusing on agile and dynamic responses to market changes, enhancing overall operational efficiency[165]. Environmental Responsibility - The Group's operations do not have a material impact on the environment, with key environmental concerns related to electricity, water, and paper consumption[15]. - The Group has implemented measures to promote environmental protection and energy conservation, including a paperless office initiative and encouraging low-carbon commuting[15]. Employee Management - The Group's employee remuneration packages include basic salary, benefits, and performance-based incentives, aimed at motivating and retaining talent[3]. - The Group has not encountered significant difficulties in recruitment or experienced major employee turnover during the reporting period[1]. - The Group's employee remuneration policy includes annual performance appraisals, which influence salary reviews and bonus allocations based on performance criteria[182]. - The Group has adopted a share option scheme to incentivize and retain key employees for ongoing support in operations and development[183]. - As of December 31, 2023, the Group had a total of 278 employees, with total staff costs amounting to RMB 54.8 million, up from RMB 30.7 million in 2022[160]. Financial Position - Total assets increased to RMB1,890.7 million, while total liabilities rose to RMB1,262.6 million[57]. - The Group's gearing ratio increased to 47.2% in 2023 from 33.6% in 2022[121]. - Cash and cash equivalents at the end of 2023 were RMB 437.9 million, up from RMB 329.1 million at the end of 2022[112]. - The Group's net debt as of December 31, 2023, was RMB 562.4 million, compared to RMB 305.8 million in 2022[121]. - The balance of trade receivables amounted to RMB536.0 million, an increase of RMB185.8 million compared to RMB350.2 million at the end of 2022, attributed to increased sales and extended credit terms[109]. - The inventory balance increased to RMB108.0 million, up RMB19.9 million from RMB88.1 million at the end of 2022, mainly due to increased inventory of human albumin solution[109].

Financial Performance - The group's revenue increased by 11.8% to RMB 2,540.1 million, up from RMB 2,271.5 million in 2022, primarily driven by a rise in sales volume of human albumin injection, contributing approximately RMB 249.8 million to the revenue growth[25] - Gross profit rose to RMB 323.3 million from RMB 305.9 million in 2022, although the gross margin decreased from 13.5% in 2022 to 12.7% in the reporting period[25] - Net profit decreased by 39.0% to RMB 42.4 million, down from RMB 69.5 million in 2022, mainly due to increased administrative expenses from the expansion of the medical beauty drug research and manufacturing segment[25] - Basic and diluted earnings per share were RMB 0.02, compared to RMB 0.03 in 2022[25] - The group reported a decrease in other income and gains to RMB 14.6 million from RMB 25.2 million in 2022[27] - Administrative expenses increased to RMB 108.9 million from RMB 81.4 million in 2022, reflecting higher operational costs[27] - The group’s financial costs, excluding credit-related financial expenses, were RMB 13,380 thousand[59] - The company's net profit attributable to owners was RMB 42.4 million for 2023, with no adjustments made for potential ordinary shares[94] - The group's net profit for 2023 was RMB 42.4 million, a decrease of RMB 27.1 million compared to RMB 69.5 million in 2022[138] Assets and Liabilities - Non-current assets increased to RMB 457,395,000 in 2023 from RMB 406,927,000 in 2022, with significant growth in property, plant, and equipment, which rose to RMB 279,083,000 from RMB 258,109,000[15] - Current liabilities surged to RMB 1,232,037,000 in 2023, up from RMB 790,585,000 in 2022, indicating a substantial increase in trade payables and bank borrowings[15] - The company reported a net asset value of RMB 201,246,000 in 2023, a decrease from RMB 226,821,000 in 2022, indicating a tightening liquidity position[15] - Total assets amounted to RMB 628,052 million, an increase from RMB 603,812 million in the previous year[29] - The total liabilities of the group as of December 31, 2023, were RMB 1,262,626 thousand, compared to RMB 820,521 thousand in the previous year[61] - The company's total borrowings amounted to RMB 241.7 million as of December 31, 2023, with bank borrowings at RMB 241.7 million[161] Dividends - The company declared a final dividend of HKD 0.39 per share for the year ending December 31, 2023, down from HKD 0.98 in 2022, totaling approximately HKD 8,000,000 compared to HKD 20,000,000 in the previous year[2] - The board proposed a final dividend of HKD 0.39 per share, totaling approximately HKD 8 million, down from HKD 20 million in 2022[25] - The company plans to pay a final dividend of HKD 0.39 per share for the year ended December 31, 2023, down from HKD 0.98 per share in 2022, totaling approximately HKD 8,000,000[77] Operational Developments - The company has implemented measures to promote environmental sustainability without incurring significant expenditures related to compliance with environmental laws and regulations during the reporting period[1] - The company has three reportable operating segments, consistent with the previous year, indicating stable operational structure[24] - The company acquired Deyang Demai Medical Beauty Hospital Co., Ltd. to enhance its medical services segment, which is now recognized as an independent reporting business unit[56] - The company successfully commenced trial production of injectable polycaprolactone microsphere facial fillers, marking a significant advancement in its research and manufacturing segment[56] - The company is advancing clinical trials for its medical beauty product, with expectations to complete trials by the second half of 2025[107] - The company has decided to suspend research on the chemical drug "Sinco 1" due to technical challenges in domestic production equipment[104] - The company is enhancing its internal marketing team to improve product promotion activities, aiming to expand its network of opinion leaders in key therapeutic areas[81] - The group is developing new products, including the "Girl's Needle" and "Privacy Needle," with various stages of development completed, including clinical trial preparations[128] Cash Flow and Financial Management - The group's cash flow from operating activities was RMB 353.7 million, significantly up from RMB 75.1 million in 2022[148] - The net cash flow from operating activities was RMB 353.7 million, while cash flow used in investing activities was RMB (63.6) million for the reporting period[165] - Financial costs decreased by RMB 3.9 million to RMB 14.4 million due to reduced bank loan interest[136] Compliance and Governance - The audit committee is responsible for reviewing and monitoring the financial reporting system and internal control procedures of the group[4] - The company appointed a new auditor, Xianji Certified Public Accountants, effective December 13, 2022, following the resignation of Ernst & Young[5] - The company received a notification regarding potential internal control violations related to a transaction amounting to USD 13 million (approximately HKD 100 million) in January 2022[6] - The company has not early adopted any new or revised International Financial Reporting Standards that have been issued but not yet effective[35] - The company confirmed that the arrangement of having the same person serve as both chairman and co-CEO will not affect the balance of power and authority between the board and management[192] - The financial figures for the year ending December 31, 2023, have been agreed upon by the company's auditors, ensuring consistency with the audited financial statements[194] Market and Industry Outlook - The group anticipates strong growth in the pharmaceutical health industry driven by aging population, increased health awareness, disease spectrum changes, and new technology applications[129]

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 1,090,126, a decrease of 3.4% compared to RMB 1,129,926 for the same period in 2022[21]. - Gross profit for the period was RMB 152,546, down 20.7% from RMB 192,198 in the previous year[21]. - Profit before tax decreased to RMB 42,769, representing a decline of 45.5% from RMB 78,568 in the prior year[21]. - Profit and total comprehensive income attributable to owners of the company was RMB 19,595, a decrease of 68.4% compared to RMB 61,923 for the same period in 2022[21]. - Basic earnings per share for the period was RMB 0.00965, down from RMB 0.03049 in the previous year[21]. - Revenue from pharmaceutical product sales for the six months ended June 30, 2023, was RMB 1,076,097,000, a decrease of 4.5% from RMB 1,127,374,000 in the same period of 2022[85]. - Medical beauty services revenue increased significantly to RMB 14,029,000 in the first half of 2023, compared to RMB 2,552,000 in the same period of 2022, representing a growth of 450.5%[85]. - Total revenue for the six months ended June 30, 2023, was RMB 1,090,126,000, down 3.5% from RMB 1,129,926,000 in the prior year[85]. - Net profit decreased by approximately RMB 42.3 million to RMB 19.6 million for the six months ended June 30, 2023, down from RMB 61.9 million for the same period in 2022[124]. - Diluted earnings per share amounted to RMB 0.00965, down from RMB 0.03048 for the same period last year[140][156]. Expenses and Costs - Selling and distribution expenses decreased to RMB 47,101, down 30.5% from RMB 67,767 in the prior year[21]. - Administrative expenses increased to RMB 48,417, up 29.8% from RMB 37,328 in the previous year[21]. - Other income and gains decreased significantly to RMB 4,220, down 63.3% from RMB 11,493 in the previous year[21]. - The Group's cost of sales was RMB 937.6 million, almost unchanged from RMB 937.7 million in the corresponding period of 2022[175]. - Other expenses during the reporting period amounted to RMB 9.0 million, an increase of RMB 7.0 million compared to RMB 2.0 million in the corresponding period of 2022, mainly due to foreign exchange losses and bank charges[182]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 820,521,000[58]. - Trade receivables as of 30 June 2023 amounted to RMB 307,842,000, down from RMB 359,478,000 as of 31 December 2022[70]. - The Group's total assets included property, plant, and equipment valued at RMB 271,144,000 as of 30 June 2023, an increase from RMB 258,109,000[68]. - Trade payables increased to RMB 639,383,000 as of June 30, 2023, from RMB 366,988,000 as of December 31, 2022, reflecting a growth of 74%[96]. - Bank loans increased to RMB 200,000,000 as of June 30, 2023, compared to RMB 180,000,000 as of December 31, 2022, representing an increase of 11.1%[99]. - The Group's total liabilities rose to RMB 1,036.6 million from RMB 820.5 million[159]. Investigations and Corporate Governance - The company is undergoing an independent forensic investigation regarding possible internal control irregularities involving transactions of approximately US$13 million[9][10]. - The final forensic investigation report was received on July 4, 2023, with further updates to be provided to investors and shareholders[12][13]. - The Group is committed to enhancing internal control systems and risk management while focusing on corporate social responsibility[193]. Strategic Initiatives and Future Outlook - The Group aims to strengthen market expansion, optimize product structures, and enhance customer satisfaction moving forward[148]. - The Group expects the batch release volume to continue to grow in the second half of 2023, significantly surpassing last year's supply[169]. - The Group is developing a series of medical beauty products based on polycaprolactone materials, aiming to enhance its product offerings in the medical beauty sector[193]. - The Group plans to expand its marketing and promotion network, strengthen management of the marketing team, and improve incentive systems to enhance profit contributions[192]. Acquisitions - The company acquired 100% equity of Deyang Yisida Biotechnology Co., Ltd. for up to RMB 66.5 million and 100% equity of Deyang Renshangren Medical Technology Co., Ltd. for up to RMB 28.5 million in May 2022[82]. - The total identifiable net assets at fair value from the acquisitions were RMB 17,909,000, with goodwill on acquisition amounting to RMB 66,536,000[83]. - The acquisition of Deyang Yisida resulted in the Company indirectly holding a 70% equity interest in Demei Company, enhancing operational control and economic benefits[112]. - The fair value of the contingent consideration related to the acquisition of Demei Company was remeasured to RMB 20,421,000 as of 30 June 2023, up from RMB 19,078,000 as of 31 December 2022[104].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Sinco Pharmaceuticals Holdings Limited 兴科蓉医药控股有限公司 （根據開曼群島法例註冊成立的有限公司） （股份代號：6833） 截 至2023年6月30日 止 六 個 月 的 中 期 業 績 公 告 財務摘要 (cid:129) 3.5% 39.8 1,090.1 報告期內，本集團收益輕微下降 或人民幣 百萬元至人民幣 2022 6 30 1,129.9 百萬元（截至 年 月 日止六個月：人民幣 百萬元），其中藥品 51.3 11.5 銷售收益減少約人民幣 百萬元，醫美服務收益增加人民幣 百萬 元。 (cid:129) 39.7 隨著本集團收益減少，報告期內，本集團毛利減少人民幣 百萬元至 152.5 2022 6 30 192.2 人民幣 百萬元（截至 年 月 日止六個月：人民幣 百萬元）， 17.0% 14.0% 而毛利率由 下降至 ，乃由於匯率波動，進而導致 ...

Financial Performance - The Group recorded revenue of RMB2,271.5 million for the Reporting Period, an increase of RMB247.4 million or 12.2% compared to RMB2,024.1 million in 2021[157]. - Revenue from human albumin solution was RMB2,257.2 million, representing an increase of approximately 14.4% or RMB283.9 million compared to 2021[158]. - The Group's net profit decreased by 48.6% to RMB69.5 million for the Reporting Period (2021: RMB135.1 million), primarily due to a decrease in gross profit from sales[118][121]. - Gross profit decreased to RMB305.9 million, down RMB59.1 million from RMB365.0 million in 2021, with a gross profit margin declining from 18.0% to 13.5%[161]. - Total assets increased to RMB1,424.3 million in 2022 from RMB1,232.8 million in 2021[127]. - Total equity attributable to owners of the Company rose to RMB603.8 million in 2022 from RMB374.9 million in 2021[127]. - Other income and gains amounted to RMB25.2 million, an increase of RMB14.3 million compared to 2021, mainly due to an increase in exchange gains[162]. Share Option Scheme - The total number of shares available for issue under the Share Option Scheme is capped at 160,000,000, which constitutes 7.87% of the issued shares of the company as of the report date[9]. - The company has adopted a Share Option Scheme to incentivize eligible participants for their contributions, effective since March 10, 2016[4]. - The maximum entitlement of each participant under the Share Option Scheme is limited to 1% of the total shares in issue within any 12-month period[5]. - The nominal consideration for accepting the grant of an option is HK$1.00[12]. - The options granted under the Share Option Scheme must be held for a minimum of one year before they can be exercised[13]. - As of December 31, 2022, there were 1,150,000 options granted to employees that remained unexercised, with all options having lapsed[20]. - The remaining life of the Share Option Scheme as of December 31, 2022, is approximately 3 years and 2 months, expiring in early 2026[8]. Corporate Governance - The company considers all independent non-executive directors to be independent according to the Listing Rules[25]. - All independent non-executive directors confirmed their independence as per the listing rules[31]. - No significant transactions or contracts involving directors were reported during the reporting period[36]. - The directors proposed for re-election at the forthcoming AGM do not have service contracts that are not determinable within one year without compensation[35]. - No equity-linked agreements were entered into by the Company during the reporting period[29]. Business Operations - The Group's principal activity involves investment holding and providing comprehensive marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China[97]. - The Group aims to expand its market presence in China through strategic marketing and promotion of imported pharmaceutical products[97]. - The Group's overall business development, operation, and management are overseen by Mr. Jin Min, who was appointed as CEO in March 2023[86]. - The Group has over 19 years of experience in the pharmaceutical industry, with key management personnel having extensive backgrounds in marketing and product management[86][88][91]. - The Group's R&D efforts are led by Mr. Wu Qingjiang, who has over 40 years of experience in pharmaceutical production and quality control[93]. Cash Flow and Financial Management - Net cash from operating activities was RMB 75.1 million, a decrease from RMB 305.7 million in 2021, mainly due to increased cash from sales and a decrease in prepayments[191]. - Net cash used in investing activities was RMB 119.3 million, compared to RMB 22.7 million in 2021, primarily due to purchases of property, plant, and equipment and acquisitions of subsidiaries[192]. - Net cash inflow from financing activities was RMB 35.0 million, a turnaround from a net outflow of RMB 97.1 million in 2021, mainly due to cash inflow from the issuance of new shares amounting to RMB 159.5 million[193]. - The Group's cash and cash equivalents at the end of the reporting period amounted to RMB 436,996,000, an increase from RMB 381,067,000 in the previous year, representing a growth of approximately 14.6%[196]. - The Group has adopted a prudent financial management approach towards its treasury policies, emphasizing strict control over outstanding receivables[200]. Market and Sales Performance - The Group's largest supplier accounted for 99.47% of total products purchased during the Reporting Period, up from 96.8% in 2021[107]. - The marketing network has expanded to cover key hospitals in major cities and further penetrated into prefectures and second-tier and third-tier cities, leading to significant growth in sales at terminal hospitals[139][142]. - The company plans to continue focusing on the terminal hospital market while supplementing with retail pharmacies to enhance market coverage and sales channel share in 2023[139][142]. - The pharmaceutical distribution business is expected to encounter new opportunities in 2023 following the easing of supply chain pressures due to the pandemic[132][134]. Dividend and Shareholder Information - The final dividend declared for the year ended December 31, 2022, is HK$0.98 cents per ordinary share, totaling HK$20,000,000, compared to HK$0 for the previous year[99][101]. - The final dividend is subject to approval by shareholders at the upcoming AGM[99][101]. - The annual general meeting (AGM) is scheduled for May 29, 2023, with a notice to be published in accordance with the Listing Rules[100].

蓬勃发展的阶段那么并呈现持续的一个增长的态势在目前双赛道的加持下公司的稀缺性及高成长性也借此得到体现那么公司管理层也特此举办本次的现在发布会希望与市场的各位朋友进行深入的一个沟通交流那么我们本次的会议将分为两个环节 向2021年减少约人民币5900万主要是因为人民币对美元汇率的贬值导致了采购成本增加公司于去年收购德美医疗美容医院全部股权向医美终端进行布局医美服务板块收入增加0.12亿元 具体内置PCL为少女针、平滑针等产品的主要成分它是医用生物降解高分子材料具有良好的生物相容性及降解性可完全降解为水和二氧化碳今年被广泛应用于各类可被人体吸收的质体上通过PCL加X理念打造填充加塑形加再生的 公司为他们提供药品市场的渠道管理服务包括价格维护 招投标以及医保商业配送渠道经销商管理药品质量和医药合规检查等公司目前依托两条业务线与国外制药生产商展开合作一是由境内子公司直接进口二是建立香港和新加坡的业务平台进行周转 最后一张是财务回顾公司目前的总市值约为8亿港币市盈率约为9.67近三年公司收益稳步增长2022年营业收入约为人民币23亿元其中人血白蛋白注射销售约为人民币20亿元公司也进入到了快速发展的阶段在开拓英美赛道的同 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Sinco Pharmaceuticals Holdings Limited 興科蓉醫藥控股有限公司 （根據開曼群島法例註冊成立的有限公司） （股份代號：6833） 截 至2022年12月31日 止 年 度 的 年 度 業 績 公 告 財務摘要 (cid:129) 報告期內，本集團收益增長12.2%或人民幣247.4百萬元至人民幣2,271.5 百萬元（2021年：人民幣2,024.1百萬元），其中人血白蛋白注射液銷售收 益增長人民幣約283.9百萬元，主要得益於銷售量的增長。 (cid:129) 報告期內，本集團毛利減少人民幣59.1百萬元至人民幣305.9百萬元（2021 年：人民幣365.0百萬元），毛利率則由2021年的18.0%下降至報告期內的 13.5%。毛利減少主要由於人民幣兌美元匯率貶值導致採購成本增加。 (cid:129) 報 告 期 內，本 集 團 純 利 減 少48.6%至 人 ...

Financial Performance - The Group's revenue increased by 33.4% or RMB 282.9 million to RMB 1,129.9 million for the Reporting Period, compared to RMB 847.0 million for the six months ended June 30, 2021[8]. - Gross profit increased by RMB 34.7 million to RMB 192.2 million, while the gross profit margin slightly decreased from 18.6% to 17.0% due to increased purchase costs[9]. - Net profit decreased by approximately RMB 13.4 million to RMB 61.9 million, primarily due to increased sales and administration expenses related to market promotion and research and development activities[10]. - Basic earnings per share amounted to RMB 0.03049 for the Reporting Period, down from RMB 0.04450 for the six months ended June 30, 2021[11]. - Diluted earnings per share also decreased to RMB 0.03048 from RMB 0.04450 in the previous period[12]. - Revenue for the six months ended June 30, 2022, was RMB 1,129.9 million, an increase of 33.4% from RMB 847.0 million in the same period of 2021[18]. - Gross profit for the same period was RMB 192.2 million, representing a 22% increase compared to RMB 157.5 million in 2021[18]. - The profit before tax decreased to RMB 78.6 million, down 14.3% from RMB 91.7 million in the previous year[18]. - The net profit margin for the period was 5.5%, a decrease from 8.9% in the previous year[18]. Revenue Sources - Revenue from sales of Human Albumin Solution increased by approximately RMB 322.0 million, while revenue from sales of antibiotics decreased by approximately RMB 41.6 million[8]. - Revenue from Human Albumin Solution was RMB 1,127.4 million, an increase of approximately 40% or RMB 322.0 million compared to the first half of 2021, driven by increased supply and sales volume[45]. - The Group temporarily halted sales of antibiotics due to adverse market demand from the ongoing COVID-19 pandemic, with plans to develop new sales channels for these products[49]. Expenses and Costs - Increased research and development expenses on aesthetic medicine contributed to the rise in overall expenses during the Reporting Period[10]. - The overall financial results indicate a need for careful management of costs to improve profitability moving forward[10]. - The Group recorded administrative expenses of RMB 37.3 million, an increase of RMB 19.9 million compared to the same period in 2021[58]. - The Group's selling and distribution expenses were approximately RMB 67.8 million, an increase of RMB 32.9 million compared to the corresponding period in 2021, mainly due to higher marketing promotion expenses[57]. Assets and Liabilities - The total assets as of June 30, 2022, were RMB 1,603.4 million, up 30% from RMB 1,232.8 million at the end of 2021[18]. - The total liabilities increased to RMB 1,007.1 million, a rise of 17.4% from RMB 857.9 million at the end of 2021[18]. - Inventory balances decreased to RMB 45.2 million from RMB 61.3 million at the end of 2021, a reduction of RMB 16.1 million due to lower inventory of human albumin solution[67]. - Trade receivables increased to RMB 228.5 million from RMB 213.2 million at the end of 2021, an increase of RMB 15.3 million due to higher sales[69]. - Trade and bills payables increased to RMB 568.3 million from RMB 422.9 million at the end of 2021, an increase of RMB 145.4 million driven by increased purchases[79]. Cash Flow and Financing - Net cash from operating activities increased to approximately RMB 87.7 million for the six months ended June 30, 2022, compared to RMB 81.7 million for the same period in 2021[88]. - Net cash used in investing activities rose significantly to RMB 90.0 million, up from RMB 1.6 million in the prior year, primarily due to the acquisition of Demei Company for RMB 68.0 million[89]. - Net cash from financing activities increased to RMB 124.6 million, compared to RMB 44.8 million in the same period last year, driven by net proceeds from bank borrowings of RMB 160.0 million[90]. - Cash and cash equivalents at the end of the period totaled RMB 456.7 million, an increase from RMB 267.0 million at the end of the previous year[87]. Strategic Initiatives - The Group's financial performance reflects a strategic focus on expanding sales channels and enhancing product offerings in the medical beauty sector[10]. - The Group acquired a 70% equity interest in Demei Company in May 2022, enhancing its capabilities in the medical beauty services sector[36]. - The research and development of the first medical beauty product, "Girl Needle," is progressing well, with pilot production expected to start in the second half of the year[42]. - The Group aims to develop a series of "PCL+X" products based on polycaprolactone raw materials to expand its medical aesthetics product line[42]. Corporate Governance and Compliance - The Group is committed to maintaining high standards of corporate governance and has complied with all applicable code provisions under the Corporate Governance Code during the Reporting Period[149]. - The Group complied with all applicable laws and regulations of the Cayman Islands, British Virgin Islands, Hong Kong, and the PRC during the Reporting Period[145]. - The Audit Committee reviewed the unaudited condensed interim results of the Group for the Reporting Period[159]. Shareholder Information - The Board resolved not to declare any interim dividend for the Reporting Period, consistent with the previous year[13]. - As of June 30, 2022, Mr. Huang holds 1,050,000,000 shares, representing 51.65% of the total shares issued, which amounts to 2,032,890,585 shares[167][170]. - Mr. Jin Min, a beneficial owner, holds 13,680,000 shares, accounting for approximately 0.67% of the total shares[167]. - The Share Option Scheme, effective from March 10, 2016, allows for the issuance of up to 160,000,000 shares, which is 7.87% of the issued share capital as of the report date[185]. Employee and Labor Relations - The Group had a total of 133 employees as of June 30, 2022[122]. - The Group's employee remuneration policy considers local market remuneration, industry standards, inflation, and employee performance[123]. - The Group did not experience major difficulties in recruitment or significant labor disputes during the reporting period[128].

Financial Performance - Revenue of the Group decreased by 1.25% or RMB25.7 million to RMB2,024.1 million for the Reporting Period (2020: RMB2,049.8 million) [11] - Gross profit increased by RMB91.2 million to RMB365.0 million, with gross profit margin rising from 13.4% in 2020 to 18.0% for the Reporting Period [12] - Net profit increased by 14.4% to RMB135.1 million for the Reporting Period (2020: RMB118.1 million) [14] - Basic and diluted earnings per share amounted to RMB0.08 for the Reporting Period (2020: RMB0.07) [15] - The Board resolved not to declare any final dividend for the Reporting Period (2020: Nil) [16] - The Group's financial performance was primarily driven by the increase in gross profit [14] - The gross profit for the year was RMB365.0 million, an increase of RMB91.2 million compared to RMB273.8 million in 2020, resulting in a gross profit margin of 18.0%, up from 13.4% in the previous year [29] - The net profit for the year was RMB135.1 million, showing growth compared to the previous year's profit of RMB118.1 million [36] Revenue Breakdown - Revenue from sales of Human Albumin Solution increased by approximately RMB84.3 million, offset by a decrease in revenue from antibiotics amounting to RMB110.0 million [11] - Revenue from human albumin solution was RMB1,973.3 million, representing an increase of approximately 4.5% or RMB84.3 million compared to 2020, driven by increased supply and sales volume [54] - Revenue from antibiotics decreased by RMB110.0 million compared to 2020, primarily due to reduced hospital inpatient numbers and the implementation of drug volume-based purchasing policies [52] - Sales of human albumin injection amounted to RMB1,973.3 million, an increase of approximately 4.5% compared to 2020 [29] - The sales revenue of antibiotic products decreased significantly to approximately RMB50.8 million, a decline of about 68.4% [29] Market and Product Development - The Company continues to focus on enhancing its product offerings and market presence [11] - The Group expects significant increases in purchase and sales volumes of human albumin in 2022, driven by recovery in plasma collection and new production capacity [32] - The aesthetic medicine market in China is projected to grow from RMB143.6 billion in 2020 to RMB318.5 billion in 2024, with a compound annual growth rate of 17.3% [38] - The non-surgical medical aesthetic market in China is expected to grow from RMB54.5 billion in 2020 to RMB98 billion in 2022, with a compound annual growth rate of 34.1% [40] - The Group initiated the development of the "Girl Needle" project with a planned investment of RMB88.5 million, targeting the non-surgical medical aesthetic market [40] - The Group's projects in the medical aesthetics industry chain have been launched in an orderly manner, anticipated to contribute new profit growth in the near future [43] Operational Efficiency - The Group recorded a cost of sales of RMB1,659.1 million, a decrease of RMB116.9 million or 6.6% compared to RMB1,776.0 million in 2020 [56] - Inventory balances decreased to RMB61.3 million from RMB242.6 million, a reduction of RMB181.3 million, attributed to increased sales of human albumin [73] - Average inventory turnover days decreased by 19 days from 52 days in 2020 to 33 days for the Reporting Period [74] - Trade receivables decreased to RMB213.6 million from RMB578.7 million, a decline of RMB365.1 million, due to enhanced credit term management [75] Cash Flow and Financial Stability - Net cash from operating activities for 2021 was RMB305.7 million, a substantial increase from RMB137.3 million in 2020 [92] - Cash and cash equivalents at the end of 2021 totaled RMB381.1 million, significantly up from RMB143.8 million at the end of 2020 [99] - The gearing ratio at the end of the reporting period was 54.5%, down from 84.8% in 2020, reflecting improved financial stability [88] - Total borrowings as of December 31, 2021, were RMB340.6 million, compared to RMB81.0 million in 2020, indicating a significant increase [86] Marketing and Distribution - The marketing network has expanded to cover key hospitals in major cities and further penetrated into second- and third-tier cities, enhancing market coverage [34] - The Group's marketing strategy focuses on enhancing distributor and promoter management to respond quickly to market changes [119] - The Group's marketing network has been expanded to include provincial, municipal, and county hospitals, improving market penetration [120] - Following the implementation of the "Two-Invoice System" in China, sales channels have become flatter, allowing manufacturers to directly reach end customers [134][135] Research and Development - R&D expenses incurred during the reporting period amounted to RMB25.5 million, reflecting the Group's commitment to innovation and product development [128][130] - The Group is developing "Sinco I," a new realgar-based chemical medicine for treating acute promyelocytic leukemia, currently in pilot experiments, with R&D expenses of RMB0.7 million incurred during the reporting period [128][129] - A collaboration with Beijing Nuokangda is underway to develop a polycaprolactone microsphere facial filler ("Girl Needle"), with total R&D expenses projected at RMB88.50 million and expected completion within 49 months [128][130] Corporate Governance and Compliance - The Group's corporate governance aims to safeguard the interests of investors, staff, suppliers, distributors, and other stakeholders [183] - The Group emphasizes compliance with laws and regulations, enhancing safety management, and actively assuming social responsibility [199] - The Group has complied with all relevant laws and regulations in the jurisdictions it operates in during the reporting period [164] Employee and Supplier Relations - The total staff costs for the Group were RMB 17.6 million in 2021, an increase from RMB 11.7 million in 2020, reflecting a growth of approximately 50.4% [141] - The Group maintains stable relationships with suppliers by providing access to the growing Chinese market, ensuring steady sales growth [151] - The Group's employee remuneration policy considers local market remuneration, industry standards, inflation, and corporate efficiency, with annual performance appraisals influencing salary reviews [141]